Search results
Results from the WOW.Com Content Network
Nervousness; Insomnia; Sleep disorder; Disturbance in attention; Depression; Confusional state; Anger; Tachycardia (fast heart rate); Chest pain; Sinusitis (nasal ...
Buspirone, sold under the brand name Buspar among others, is an anxiolytic, a medication primarily used to treat anxiety disorders, particularly generalized anxiety disorder (GAD). [ 10 ] [ 11 ] It is a serotonin 5-HT 1A receptor partial agonist , increasing action at serotonin receptors in the brain. [ 3 ]
Over-rapid withdrawal, lack of explanation, and failure to reassure individuals that they are experiencing temporary withdrawal symptoms led some people to experience increased panic and fears they are going mad, with some people developing a condition similar to post-traumatic stress disorder as a result. A slow withdrawal regimen, coupled ...
Buspar – an anxiolytic used to treat generalized anxiety disorder; Belbuca, Buprenex, Butrans, Subutex, Probuohine (buprenorphine) - an opioid medicine used to treat moderate to severe pain, and in some formulations to treat opioid use disorder; Belsomra – used to treat insomnia
Most men should start getting screened when they reach 50, and Black men, people with a family history of prostate cancer, and others with a higher risk should get screened starting at 40.
The main indication for SSRIs is major depressive disorder; however, they are frequently prescribed for anxiety disorders, such as social anxiety disorder, generalized anxiety disorder, panic disorder, obsessive–compulsive disorder (OCD), eating disorders, chronic pain, and, in some cases, for posttraumatic stress disorder (PTSD).
Potentiates warfarin activity, leading to excessive anticoagulation and bleeding [3] [13] Dong quai female ginseng Angelica sinensis: May induce uterine contractions; contraindicated when pregnant or nursing [14] European Mistletoe: common mistletoe Viscum album: Toxic to cardio and central nervous systems, gastrointestinal bleeding [3] Ephedra ...
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...